National Bank Of Canada Bei Gene, Ltd. Transaction History

National Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$141.8 - $181.47 $2,694 - $3,447	19 Added 57.58%	52 $8,000
Q3 2023 Oct 10, 2023	SELL	$179.87 - $225.13 $5.79 Million - $7.25 Million	-32,197 Reduced 99.9%	33 $5,000
Q2 2023 Jul 26, 2023	BUY	$178.3 - $266.78 $5.74 Million - $8.59 Million	32,200 Added 107333.33%	32,230 $5.75 Million
Q4 2022 Jan 24, 2023	SELL	$125.51 - $229.3 $376 - $687	-3 Reduced 9.09%	30 $0
Q3 2022 Oct 13, 2022	SELL	$131.8 - $202.24 $922 - $1,415	-7 Reduced 17.5%	33 $4,000
Q2 2022 Jul 28, 2022	BUY	$121.11 - $216.05 $3,512 - $6,265	29 Added 263.64%	40 $6,000
Q1 2022 May 05, 2022	BUY	$146.52 - $269.56 $1,172 - $2,156	8 Added 266.67%	11 $2,000
Q4 2021 Jan 24, 2022	BUY	$248.56 - $389.34 $745 - $1,168	3 New	3 $1,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

Stay updated on National Bank Of Canada with notifications on news.